Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?

Gilead’s dividend is continuing to grow and HIV revenues are described as staying strong, indicating a still-healthy near-term cash engine. However, the article highlights that the broader business is heavily dependent on a single blockbuster drug, with patent expiration already mapped out about a decade in advance. This mix of durable cash generation but clear long-dated product-life-cycle risk is a cautious setup for investors.